Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>A combination of programmed cell death protein‐1 (PD‐1)/programmed cell death ligand‐1 (PD‐L1) inhibitors and radiotherapy (RT) is increasingly being used to treat non‐small‐cell lung cancer (NSCLC). However, the safety and efficacy of this approach remains controversial. We performed a systematic review and meta‐analysis to summarize the related research.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We searched the China Biology Medicine, EMBASE, Cochrane Library, and PubMed databases for all the relevant studies. The Stata software, version 12.0 was used for the meta‐analysis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The study included 20 clinical trials that enrolled 2027 patients with NSCLC. Compared with non‐combination therapy, combination therapy using PD‐1/PD‐L1 inhibitors and RT was associated with prolonged overall survival (OS) (1‐year OS: odds ratio [OR] 1.77, 95% confidence interval [CI] 1.35–2.33, <i>p</i> = 0.000; 2‐year OS: OR 1.77, 95% CI 1.35–2.33, <i>p</i> = 0.000) and progression‐free survival (PFS) (0.5‐year PFS: OR 1.83, 95% CI 1.13–2.98, <i>p</i> = 0.014; 1‐year PFS: OR 2.09, 95% CI 1.29–3.38, <i>p</i> = 0.003; 2‐year PFS: OR 2.47, 95% CI 1.13–5.37, <i>p</i> = 0.023). Combination therapy also improved the objective response rate (OR 2.76, 95% CI 1.06–7.19, <i>p</i> = 0.038) and disease control rate (OR 1.80, 95% CI 1.21–2.68, <i>p</i> = 0.004). This meta‐analysis showed that compared with non‐combination therapy, combination therapy using PD‐1/PD‐L1 inhibitors and RT did not increase the serious adverse event rates (≥grade 3); however, this approach increased the rate of grade 1–2 immune‐related or radiation pneumonitis. Subgroup analyses revealed that the sequence of PD‐1/PD‐L1 inhibitors followed RT outperformed in which concurrent PD‐1/PD‐L1 inhibitor and RT followed PD‐1/PD‐L1 inhibitor. Combination of stereotactic body RT or stereotactic radiosurgery with PD‐1/PD‐L1 inhibitors may be more effective than a combination of conventional RT with PD‐1/PD‐L1 inhibitors in patients with advanced NSCLC. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Combination therapy using PD‐1/PD‐L1 inhibitors and RT may improve OS, PFS, and tumor response rates without an increase in serious adverse events in patients with advanced NSCLC. However, combination therapy was shown to increase the incidence of mild pneumonitis.</p></section>

Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

Progress in PD-1/PD-L1 inhibitors combined with other approaches in the treatment of non-small cell lung cancer

Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?

Shining Light on Advanced NSCLC in 2017: Combining Immune Checkpoint Inhibitors.

Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors

Impact of Clinicopathological Features on the Efficacy of Immune Checkpoint Inhibitors Plus Conventional Treatment in Patients with Advanced Lung Cancer

Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis

SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges

The safety and efficacy of anti-PD-1 inhibitor-based combinational therapy in non-small cell lung cancer patients with oncogenic alterations

Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy

Safety Analysis of Immunochemotherapy Combined With Consolidative Thoracic Radiotherapy for Extensive-stage Small Cell Lung Cancer

Efficacy and Safety of Combining Radiotherapy with Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: a Real-World Study.

Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics

The Combination of Radiotherapy with Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients

Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms

Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non–Small Cell Lung Cancer

Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy

Radiation and immunotherapy: emerging mechanisms of synergy

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications

The Efficacy and Safety of Immune Checkpoints Inhibitors Plus Radiotherapy As a Combination Therapy for Advanced Non-Small Cell Lung Carcinoma: a Meta-Analysis